Clinical trials in dementia with propentofylline

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Xanthine derivatives, such as propentofylline, were investigated for potential therapeutic effects in neurodegenerative conditions.
• Alzheimer's disease and vascular dementia represent significant challenges in cognitive health management.

Purpose of the Study:

• To evaluate the efficacy and safety of propentofylline in patients diagnosed with mild to moderate Alzheimer's disease or vascular dementia.
• To assess the impact of propentofylline on cognitive function, global status, and daily living activities.

Main Methods:

• Four double-blind, placebo-controlled, randomized studies were conducted.
• A total of 901 patients with Alzheimer's disease and 359 with vascular dementia received propentofylline (3 x 300 mg daily) or placebo for up to 12 months.
• Efficacy was assessed using cognitive, global, and activities of daily living measures.

Main Results:

• Propentofylline yielded statistically significant and clinically relevant improvements compared to placebo in both Alzheimer's disease and vascular dementia patient groups.
• The drug was well-tolerated, with no significant adverse effects on laboratory findings.
• Adverse events related to propentofylline were predominantly minor, transient, and affected the digestive and nervous systems.

Conclusions:

• Propentofylline demonstrates efficacy in improving cognitive and global functions in patients with mild to moderate Alzheimer's disease and vascular dementia.
• The safety profile of propentofylline is favorable, indicating good tolerability in the studied patient populations.
• Propentofylline represents a potentially beneficial therapeutic option for managing dementia symptoms.